• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    This Old Dominion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

    6/5/24 9:02:16 AM ET
    $JAZZ
    $ODFL
    $PRLB
    $SPIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Trucking Freight/Courier Services
    Industrials
    Get the next $JAZZ alert in real time by email

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

    • Guggenheim analyst Subbu Nambi initiated coverage on Twist Bioscience Corporation (NASDAQ:TWST) with a Buy rating, while announcing a price target of $53. Twist Bioscience shares gained 6.8% to close at $46.98 on Tuesday. See how other analysts view this stock.
    • BMO Capital analyst Fadi Chamoun initiated coverage on Old Dominion Freight Line, Inc. (NASDAQ:ODFL) with an Outperform rating and announced a price target of $210. Old Dominion Freight Line shares rose 1.7% to settle at $172.14 on Tuesday. See how other analysts view this stock.
    • Cantor Fitzgerald analyst Troy Jensen initiated coverage on Proto Labs, Inc. (NYSE:PRLB) with an Overweight rating, while announcing a price target of $44. Proto Labs shares fell 0.2% to settle at $30.32 on Tuesday. See how other analysts view this stock.
    • Goldman Sachs analyst Madhu Kumar initiated coverage on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) with a Buy rating and announced a price target of $169. Jazz Pharmaceuticals shares fell 1.2% to close at $104.48 on Tuesday. See how other analysts view this stock.
    • Craig-Hallum analyst Jeff Van Rhee initiated coverage on Spire Global, Inc. (NYSE:SPIR) with a Buy rating, while announcing a price target of $13. Spire Global shares rose 1.1% to settle at $9.33 on Tuesday. See how other analysts view this stock.

    Check This Out: Top 4 Health Care Stocks That Are Preparing To Pump This Month

    Get the next $JAZZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JAZZ
    $ODFL
    $PRLB
    $SPIR

    CompanyDatePrice TargetRatingAnalyst
    Old Dominion Freight Line Inc.
    $ODFL
    2/12/2026$220.00Hold → Buy
    Argus
    Old Dominion Freight Line Inc.
    $ODFL
    2/6/2026$216.00Buy → Neutral
    Citigroup
    Old Dominion Freight Line Inc.
    $ODFL
    2/6/2026$205.00Buy → Hold
    Deutsche Bank
    Old Dominion Freight Line Inc.
    $ODFL
    2/5/2026$204.00Neutral → Underperform
    Robert W. Baird
    Old Dominion Freight Line Inc.
    $ODFL
    2/5/2026$167.00 → $180.00Hold
    TD Cowen
    Spire Global Inc.
    $SPIR
    1/6/2026$14.00Buy
    H.C. Wainwright
    Spire Global Inc.
    $SPIR
    12/24/2025Buy → Neutral
    Alliance Global Partners
    Old Dominion Freight Line Inc.
    $ODFL
    12/8/2025$190.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $JAZZ
    $ODFL
    $PRLB
    $SPIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gawlick Rainer bought $75,105 worth of shares (1,715 units at $43.79), increasing direct ownership by 4% to 43,883 units (SEC Form 4)

    4 - Proto Labs Inc (0001443669) (Issuer)

    8/7/25 4:09:01 PM ET
    $PRLB
    Metal Fabrications
    Industrials

    President and CEO Krishna Suresh bought $75,055 worth of shares (1,725 units at $43.51), increasing direct ownership by 11% to 18,021 units (SEC Form 4)

    4 - Proto Labs Inc (0001443669) (Issuer)

    8/6/25 8:48:14 PM ET
    $PRLB
    Metal Fabrications
    Industrials

    Director Mulligan Seamus bought $9,993,082 worth of Ordinary Shares (101,621 units at $98.34) (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    5/13/25 6:51:34 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    $ODFL
    $PRLB
    $SPIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operations Officer Kenison Michael R. covered exercise/tax liability with 2,684 shares, decreasing direct ownership by 8% to 31,842 units (SEC Form 4)

    4 - Proto Labs Inc (0001443669) (Issuer)

    2/12/26 4:50:27 PM ET
    $PRLB
    Metal Fabrications
    Industrials

    Chief Financial Officer Schumacher Daniel covered exercise/tax liability with 6,809 shares and exercised 3,135 shares at a strike of $33.84, decreasing direct ownership by 8% to 43,971 units (SEC Form 4)

    4 - Proto Labs Inc (0001443669) (Issuer)

    2/12/26 4:48:48 PM ET
    $PRLB
    Metal Fabrications
    Industrials

    Chief Accounting Officer Werner Robert F. gifted 2,000 shares, decreasing direct ownership by 3% to 56,738 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    2/11/26 4:05:07 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JAZZ
    $ODFL
    $PRLB
    $SPIR
    SEC Filings

    View All

    Twist Bioscience Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Twist Bioscience Corp (0001581280) (Filer)

    2/6/26 5:25:52 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Twist Bioscience Corporation

    144 - Twist Bioscience Corp (0001581280) (Subject)

    2/6/26 3:16:13 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Proto Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K/A - Proto Labs Inc (0001443669) (Filer)

    2/6/26 2:50:30 PM ET
    $PRLB
    Metal Fabrications
    Industrials

    $JAZZ
    $ODFL
    $PRLB
    $SPIR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 12, 2021 - FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

    For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl

    8/12/21 4:25:43 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    March 26, 2021 - Coronavirus (COVID-19) Update: March 26, 2021

    For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato

    3/26/21 3:51:09 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JAZZ
    $ODFL
    $PRLB
    $SPIR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026

    DUBLIN, Feb. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss the results and provide a business and financial update.   Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the webcast will be availa

    2/10/26 4:15:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes

    Twist TrueAmp Library Preparation Kit with in-house developed enzymes including new Twist TrueAmp Polymerase Twist PCR-Free WGS Library Preparation Kit designed to meet the needs of the growing whole genome sequencing market New kits compatible with additional Twist NGS Applications tools for complete target enrichment and WGS library prep workflows Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research. The Twist Tr

    2/10/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protolabs Reports Financial Results for the Fourth Quarter and Full Year 2025

    Record Quarterly Revenue of $136.5 Million, a 12.1% Increase Year-Over-Year Record Annual Revenue of $533.1 Million, a 6.4% Increase Year-Over-Year Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE:PRLB), the world's leading provider of digital manufacturing services, today announced financial results for the fourth quarter and full year ended December 31, 2025. "Protolabs closed 2025 with strong momentum, delivering accelerated growth, record revenue, and solid earnings in the fourth quarter," said President and Chief Executive Officer Suresh Krishna. "2026 is a pivotal year of transformation and acceleration as we establish the foundation to execute our long-term strategic pilla

    2/6/26 6:00:00 AM ET
    $PRLB
    Metal Fabrications
    Industrials

    $JAZZ
    $ODFL
    $PRLB
    $SPIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Old Dominion upgraded by Argus with a new price target

    Argus upgraded Old Dominion from Hold to Buy and set a new price target of $220.00

    2/12/26 9:50:56 AM ET
    $ODFL
    Trucking Freight/Courier Services
    Industrials

    Old Dominion downgraded by Citigroup with a new price target

    Citigroup downgraded Old Dominion from Buy to Neutral and set a new price target of $216.00

    2/6/26 8:16:07 AM ET
    $ODFL
    Trucking Freight/Courier Services
    Industrials

    Old Dominion downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Old Dominion from Buy to Hold and set a new price target of $205.00

    2/6/26 8:10:20 AM ET
    $ODFL
    Trucking Freight/Courier Services
    Industrials

    $JAZZ
    $ODFL
    $PRLB
    $SPIR
    Leadership Updates

    Live Leadership Updates

    View All

    Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

    Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions DUBLIN, Jan. 8, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga joined Jazz in April 2025 through the acquisition of Chimerix Inc., where he served as chief operating and commercial officer. In that role, he directed corporate strategy including the successful sale of Chimerix to Jazz. In addition to leading the transaction process and alliance management at Chimerix, he helped navigate a complex regulatory env

    1/8/26 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

    Dr. Love, a biopharmaceutical industry veteran, brings extensive executive leadership and board experience with proven success in creating shareholder value DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that Ted W. Love, M.D., has been appointed to the Company's Board of Directors, effective December 1, 2025. Dr. Love brings more than 30 years of expertise in drug development and global commercialization to the Company's Board.  "We are thrilled to welcome Ted to the Board," said Renee Gala, president and CEO, Jazz Pharmaceuticals. "His proven success in the biopharmaceutical industry and track record driving scientific innovation, commercial su

    10/28/25 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jersey Mike's Elects Fran Horowitz and Cheryl S. Miller to its Board of Directors

    New directors bring global brand leadership and broad franchise experience to Jersey Mike's MANASQUAN, N.J., Oct. 28, 2025 /PRNewswire/ -- Jersey Mike's Subs ("Jersey Mike's" or the "Company"), a leading franchisor of fast-casual sandwich shops known for its fresh sliced and fresh grilled subs, today announced the appointment of Fran Horowitz and Cheryl S. Miller to its Board of Directors, effective immediately. The new additions bring deep experience in global brand building, franchise management, and executive leadership to support the Company's continued momentum and growth initiatives. Charlie Morrison, Chief Executive Officer of Jersey Mike's, said: "I am pleased to welcome Fran and C

    10/28/25 10:00:00 AM ET
    $ANF
    $CELH
    $ODFL
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary
    Beverages (Production/Distribution)
    Consumer Staples

    $JAZZ
    $ODFL
    $PRLB
    $SPIR
    Financials

    Live finance-specific insights

    View All

    Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026

    DUBLIN, Feb. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss the results and provide a business and financial update.   Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the webcast will be availa

    2/10/26 4:15:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Protolabs Reports Financial Results for the Fourth Quarter and Full Year 2025

    Record Quarterly Revenue of $136.5 Million, a 12.1% Increase Year-Over-Year Record Annual Revenue of $533.1 Million, a 6.4% Increase Year-Over-Year Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE:PRLB), the world's leading provider of digital manufacturing services, today announced financial results for the fourth quarter and full year ended December 31, 2025. "Protolabs closed 2025 with strong momentum, delivering accelerated growth, record revenue, and solid earnings in the fourth quarter," said President and Chief Executive Officer Suresh Krishna. "2026 is a pivotal year of transformation and acceleration as we establish the foundation to execute our long-term strategic pilla

    2/6/26 6:00:00 AM ET
    $PRLB
    Metal Fabrications
    Industrials

    Old Dominion Freight Line Reports Fourth Quarter 2025 Earnings Per Diluted Share of $1.09

    Quarterly Cash Dividend to Increase 3.6% to $0.29 Per Share Old Dominion Freight Line, Inc. (NASDAQ:ODFL) today announced financial results for the three-month and twelve-month periods ended December 31, 2025.   Three Months Ended       Twelve Months Ended       December 31,       December 31,     (In thousands, except per share amounts) 2025   2024   % Chg.   2025   2024   % Chg. Total revenue $ 1,307,296   $ 1,385,829   (5.7)%   $ 5,496,389  

    2/4/26 7:00:00 AM ET
    $ODFL
    Trucking Freight/Courier Services
    Industrials

    $JAZZ
    $ODFL
    $PRLB
    $SPIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Old Dominion Freight Line Inc.

    SC 13G/A - OLD DOMINION FREIGHT LINE, INC. (0000878927) (Subject)

    11/14/24 1:22:36 PM ET
    $ODFL
    Trucking Freight/Courier Services
    Industrials

    Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

    SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    11/8/24 2:38:08 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Twist Bioscience Corporation

    SC 13G - Twist Bioscience Corp (0001581280) (Subject)

    11/8/24 9:39:34 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care